Pharmacokinetics, Immunogenicity, and Safety of a Modified YTE Antibody in Healthy Adults.

Clin Pharmacol Drug DevOct 1, 2026
Clinical ResearchInfectious Diseases

Maria Rosario, Jan de Hoon, Flonza Isa et al.

✦ AI-curated · Sources linked

In 30 seconds

This Phase I randomized controlled trial evaluated the pharmacokinetics, immunogenicity, and safety of REGN17092, a modified YTE antibody targeting SARS-CoV-2, in 40 healthy adults. Results indicated a dose-proportional increase in serum concentrations and a half-life of 80-90 days, with no observed anti-drug antibody responses.

Key findings

  • Mean concentrations of REGN17092 increased in a dose-proportional manner.
  • REGN17092 demonstrated a half-life of 80-90 days.
  • No anti-drug antibody responses were observed.
  • The study highlighted the tolerability of REGN17092.

Why it matters

Understanding the pharmacokinetics and safety profile of new therapeutic antibodies is crucial for clinicians, especially in the context of evolving viral variants. This study provides insights into the potential longevity and tolerability of REGN17092.

Source

PubMed · PMID 42811441

Published in Clin Pharmacol Drug Dev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.